CA2953363C - Ophthalmic composition comprising atropine or atropine sulphate - Google Patents

Ophthalmic composition comprising atropine or atropine sulphate Download PDF

Info

Publication number
CA2953363C
CA2953363C CA2953363A CA2953363A CA2953363C CA 2953363 C CA2953363 C CA 2953363C CA 2953363 A CA2953363 A CA 2953363A CA 2953363 A CA2953363 A CA 2953363A CA 2953363 C CA2953363 C CA 2953363C
Authority
CA
Canada
Prior art keywords
ophthalmic composition
composition
ophthalmic
agent
atropine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2953363A
Other languages
English (en)
French (fr)
Other versions
CA2953363A1 (en
Inventor
Gregory I. Ostrow
Kenneth J. Widder
David S. Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sydnexis Inc
Original Assignee
Sydnexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868660&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2953363(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sydnexis Inc filed Critical Sydnexis Inc
Publication of CA2953363A1 publication Critical patent/CA2953363A1/en
Application granted granted Critical
Publication of CA2953363C publication Critical patent/CA2953363C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2953363A 2014-06-24 2015-06-23 Ophthalmic composition comprising atropine or atropine sulphate Active CA2953363C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462016502P 2014-06-24 2014-06-24
US62/016,502 2014-06-24
US201462096433P 2014-12-23 2014-12-23
US62/096,433 2014-12-23
US201562151926P 2015-04-23 2015-04-23
US62/151,926 2015-04-23
US14/726,139 2015-05-29
US14/726,139 US9421199B2 (en) 2014-06-24 2015-05-29 Ophthalmic composition
PCT/US2015/037249 WO2015200361A1 (en) 2014-06-24 2015-06-23 Ophthalmic composition

Publications (2)

Publication Number Publication Date
CA2953363A1 CA2953363A1 (en) 2015-12-30
CA2953363C true CA2953363C (en) 2024-02-27

Family

ID=54868660

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953363A Active CA2953363C (en) 2014-06-24 2015-06-23 Ophthalmic composition comprising atropine or atropine sulphate

Country Status (25)

Country Link
US (12) US9421199B2 (https=)
EP (3) EP3160471B1 (https=)
JP (6) JP6678362B2 (https=)
KR (4) KR102710491B1 (https=)
CN (3) CN115192520A (https=)
BR (1) BR112016030368B1 (https=)
CA (1) CA2953363C (https=)
CY (1) CY1125505T1 (https=)
DK (1) DK3160471T3 (https=)
ES (1) ES2924243T3 (https=)
FI (1) FIC20250034I1 (https=)
FR (1) FR25C1045I1 (https=)
HR (1) HRP20220972T1 (https=)
HU (2) HUE059521T2 (https=)
IL (1) IL249643B (https=)
LT (1) LT3160471T (https=)
NO (1) NO2025049I1 (https=)
PL (1) PL3160471T3 (https=)
PT (1) PT3160471T (https=)
RS (1) RS63486B1 (https=)
SG (3) SG10201913976SA (https=)
SI (1) SI3160471T1 (https=)
SM (1) SMT202200447T1 (https=)
TW (4) TWI867694B (https=)
WO (1) WO2015200361A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220288114A1 (en) * 2019-07-11 2022-09-15 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
EP3373976B1 (en) 2015-11-10 2024-01-03 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
US10918694B2 (en) 2016-02-29 2021-02-16 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof
MY190011A (en) * 2016-04-11 2022-03-22 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
ES2929368T3 (es) * 2016-05-25 2022-11-28 Singapore Health Serv Pte Ltd Composición acuosa que contiene atropina
JP2020509085A (ja) * 2017-02-21 2020-03-26 シンガポール ヘルス サービシーズ プライベート リミテッド アトロピンを含む、近視の発症を予防するまたは遅らせるための組成物および方法
WO2018174149A1 (en) * 2017-03-23 2018-09-27 Singapore Health Services Pte Ltd Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
DK3600456T3 (da) 2017-03-27 2023-10-02 Regeneron Pharma Fremgangsmåde til sterilisering
RU2745603C1 (ru) * 2017-05-11 2021-03-29 Невакар Инк. Фармацевтические композиции атропина
JP7227163B2 (ja) 2017-06-10 2023-02-21 アイノビア，インコーポレイティド 流体を取扱い、目に流体を送出するための方法および装置
WO2019018749A1 (en) 2017-07-20 2019-01-24 Alan Laboratories, Inc. COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA
AU2018371787A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
KR20250109788A (ko) 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료
CN114557955B (zh) 2018-09-25 2024-06-18 沈阳兴齐眼药股份有限公司 药物组合物、其制备方法和用途
CN110934869B (zh) * 2018-09-25 2023-07-04 沈阳兴齐眼药股份有限公司 一种阿托品药物组合物和药盒产品
JP2022519580A (ja) * 2019-02-06 2022-03-24 ティアークリアー コープ． 複合体化剤を含む眼科用製剤から防腐剤を除去するためのシステムおよび方法
PT3701938T (pt) 2019-03-01 2024-01-31 Medivis S R L Formulações oftálmicas à base de atropina
KR20210151848A (ko) * 2019-03-26 2021-12-14 아우라 바이오사시언시스, 인크. 인간 파필로마바이러스 나노입자 제제
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
KR102308566B1 (ko) * 2019-05-28 2021-10-05 서울대학교병원 녹내장 안약의 약물이상반응 진단 키트
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
EP4057941A4 (en) * 2019-11-15 2024-05-29 Silk Technologies Ltd. Stable formulations of silk-derived protein
WO2021119513A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
JP2023505841A (ja) * 2019-12-16 2023-02-13 シドネキシス，インク． Ｄ２ｏを含む眼科用組成物
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
WO2022026796A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for delivering meibum-like materials
US20220105101A1 (en) 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Efficient brinzolamide and brimonidine compositions
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN114306331B (zh) * 2020-10-10 2023-07-18 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
KR102245533B1 (ko) * 2020-11-02 2021-04-28 주식회사 지게차코리아 운송수단용 림 및 이의 제조방법
AU2022212108A1 (en) * 2021-01-28 2023-08-17 Glaukos Corporation Formulations
JP7749020B2 (ja) * 2021-02-03 2025-10-03 エーディーエス・セラピューティクス・エルエルシー 局所眼科用組成物
WO2022169959A1 (en) * 2021-02-04 2022-08-11 Sydnexis, Inc. Ophthalmic compositions for presbyopia
WO2022172089A1 (en) * 2021-02-12 2022-08-18 I Optima Ltd. Compound, method and system for ophthalmic surgery
US20240156724A1 (en) * 2021-03-16 2024-05-16 Vyluma Inc. Multi-Dose Container for Ophthalmic Compositions
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
JP2024531836A (ja) * 2021-09-13 2024-08-29 オウプーシーファン ファーマシューティカル テクノロジー カンパニー リミテッド アトロピン点眼液及びその調製方法
US12396534B2 (en) 2021-10-08 2025-08-26 Johnson & Johnson Vision Care, Inc. Multi-material lens package
WO2023081891A2 (en) * 2021-11-05 2023-05-11 Calm Water Therapeutics Llc Methods for using bioadhesive and steric interactions of copolymers with at least two moieties to minimize adverse effects mediated by external influences on cell, tissue, organ system, and organism biology
EP4489858A4 (en) * 2022-03-07 2026-01-21 Harrow Ip Llc Extended-release pharmaceutical compositions for the treatment of eye conditions
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
WO2023171989A1 (ko) * 2022-03-11 2023-09-14 주식회사 메디치바이오 안질환 예방 또는 치료용 약학 조성물
EP4698187A2 (en) * 2022-05-03 2026-02-25 IVIEW Therapeutics, Inc. Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases
WO2024015959A1 (en) 2022-07-15 2024-01-18 Praful Doshi Methods of making and using contact lenses including medicaments and stabilizers of labile components such as drugs
US20240033260A1 (en) * 2022-07-26 2024-02-01 The Chinese University Of Hong Kong Low-concentration atropine for myopia prevention (lamp-2) study
WO2024091789A1 (en) * 2022-10-26 2024-05-02 Vyluma Inc. Childhood atropine for myopia progression
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121079085A (zh) * 2023-03-16 2025-12-05 格劳科斯公司 眼科乳膏剂制剂及其用途
TW202525288A (zh) * 2023-10-26 2025-07-01 英商庫博光學國際有限公司 液體組合物
WO2025212792A1 (en) * 2024-04-03 2025-10-09 Sydnexis, Inc. Methods and compositions for increasing pupil dilation
WO2026038024A1 (en) * 2024-08-13 2026-02-19 Coopervision International Limited Liquid composition

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382124B1 (en) 1958-07-18 1994-10-04 Rohm & Haas Process for preparing macroreticular resins, copolymers and products of said process
NL284933A (https=) 1961-10-31
DE1518819B1 (de) 1965-04-03 1969-12-04 Basf Ag Loesungsvermittler fuer pharmazeutische Zwecke
SE352811B (https=) 1971-06-04 1973-01-15 Pharmacia Ab
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4952586A (en) 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3644984A1 (de) 1986-07-01 1988-07-07 Eberhardt Schlueter Patrone oder ampulle fuer eine injektionsvorrichtung sowie selbsttaetige injektionsvorrichtung
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4852582A (en) 1987-09-11 1989-08-01 Pell Donald M Method and kit for measuring the effectiveness of bronchodilators
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
FR2638428B1 (fr) 1988-10-28 1990-12-28 Transphyto Sa Conditionnement pour liquides a epurer
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5259998A (en) 1991-10-04 1993-11-09 Chiron Ophthalmics, Inc. Method for casting dissolvable ophthalmic shields in a mold
US5492689A (en) 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5260000A (en) 1992-08-03 1993-11-09 Bausch & Lomb Incorporated Process for making silicone containing hydrogel lenses
FR2702660B1 (fr) 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US5840770A (en) 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
US5490938A (en) 1993-12-20 1996-02-13 Biopolymerix, Inc. Liquid dispenser for sterile solutions
ATE317690T1 (de) 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
CZ285636B6 (cs) 1995-02-07 1999-10-13 Ústav Makromolekulární Chemie Av Čr Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby
WO1997016192A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
CA2250780A1 (en) 1996-04-10 1997-10-16 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US20030157187A1 (en) 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
FR2770843B1 (fr) 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
US6149670A (en) 1999-03-11 2000-11-21 Alsius Corporation Method and system for treating cardiac arrest using hypothermia
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
IN185228B (https=) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
AU779783B2 (en) 1999-05-17 2005-02-10 Eisai Inc. Improved cellular uptake of bioactive agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
CN1323595A (zh) 2000-05-11 2001-11-28 朱卫国 用于青光眼的药物组合物
US20050251254A1 (en) 2000-06-02 2005-11-10 Brady Daniel G Method of implanting accommodating intraocular lenses
ES2396598T3 (es) 2000-08-25 2013-02-22 Senju Pharmaceutical Co., Ltd. Preparaciones en forma de suspensiones acuosas
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL158904A0 (en) 2001-05-25 2004-05-12 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
CN1206988C (zh) 2002-05-10 2005-06-22 刘继东 硫酸阿托品眼用凝胶
AU2004264974A1 (en) 2003-08-15 2005-02-24 Arius Two, Inc. Adhesive bioerodible transmucosal drug delivery system
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
NZ579516A (en) 2004-01-27 2011-01-28 Osteotech Inc Stabilized bone graft
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US7659260B2 (en) 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
MX2007009417A (es) 2005-02-04 2007-08-17 Univ Auburn Sistema de suministro de farmaco de contacto.
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
US20100022495A1 (en) 2005-11-01 2010-01-28 President And Fellows Of Harvard College Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
CN101049287A (zh) * 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US7691099B2 (en) 2006-07-12 2010-04-06 Ntk Enterprises, Inc. Deuterated ocular solutions for LTK and other surgical eye procedures
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
CN101327216A (zh) 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
NZ584275A (en) * 2007-10-08 2012-06-29 Fovea Pharmaceuticals Aqueous cyclosporine ophthalmic formulations
US7815605B2 (en) 2007-11-28 2010-10-19 Souter Steve R Emergency medication pump injection system
CN101468214A (zh) * 2007-12-27 2009-07-01 上海华捷视医疗设备有限公司 一种眼科手术用重水及其制备方法
EP2508189A3 (de) 2008-04-20 2012-11-07 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor
EP2370054B1 (en) 2008-12-11 2015-10-07 Massachusetts Institute of Technology Contact lens drug delivery device
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
US8883214B2 (en) 2009-01-13 2014-11-11 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
TW201043211A (en) 2009-03-31 2010-12-16 Johnson & Johnson Vision Care Inc Punctal plugs
EP2464387A4 (en) * 2009-08-12 2013-05-15 Seros Medical Llc DEUTERATED WATER SOLUTION AND RIBOFLAVIN FOR EXTENDED OXYGEN SINGULET LIFETIME IN THE TREATMENT OF OCULAR TISSUE AND METHOD OF USE
FR2950036B1 (fr) 2009-09-11 2011-12-16 Rexam Pharma La Verpilliere Dispositif de distribution de liquide
FR2952040B1 (fr) 2009-10-29 2011-12-30 Rexam Pharma La Verpilliere Dispositif de distribution de liquide sous forme de gouttes
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
EP2563303A4 (en) * 2010-04-30 2013-11-06 Seros Medical Llc METHOD AND APPARATUS FOR TREATING OCULAR TISSUE USING COMBINED MODALITIES
TWI424663B (zh) 2010-07-01 2014-01-21 Joy Ride Tech Co Ltd A motor with heat pipe
EP2593056B1 (en) 2010-07-15 2020-10-21 Eyenovia, Inc. Drop generating device
WO2012009696A2 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
JP5823766B2 (ja) * 2010-07-30 2015-11-25 大塚製薬株式会社 医薬組成物
TW201217533A (en) 2010-08-04 2012-05-01 Bayer Pharma AG Genomics of actinoplanes utahensis
BR112013021048A2 (pt) * 2011-02-18 2016-10-18 M S Appasmy Associates composição oftálmica para permitir dilatação de pupilas
CN103501764A (zh) 2011-03-03 2014-01-08 阿勒根公司 基于硅酮的眼科制剂
MX346312B (es) 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
KR101967938B1 (ko) 2011-05-12 2019-04-10 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
TW201302244A (zh) 2011-07-08 2013-01-16 Univ Nat Chiao Tung 載藥型隱形眼鏡及其製備方法
WO2013079580A1 (en) 2011-11-29 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
US20170304152A1 (en) 2012-02-01 2017-10-26 Certa Dose, Inc. Apparatuses, methods, and systems for delivering medication using medication kits
WO2013129322A1 (ja) * 2012-02-27 2013-09-06 ロート製薬株式会社 眼科用組成物
US9814729B2 (en) 2012-03-14 2017-11-14 The Regents Of The University Of California Nerve agent antidotes
KR102310775B1 (ko) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
MX2014013714A (es) 2012-05-11 2015-08-10 Cipla Ltd Composicion farmaceutica.
WO2013173321A1 (en) 2012-05-14 2013-11-21 Corinthian Ophthalmic, Inc. Laminar flow droplet generator device and methods of use
EA201492094A1 (ru) 2012-05-15 2015-04-30 Айновиа, Инк. Эжекторные устройства, способы, возбудители и схемы для них
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
US9827250B2 (en) 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
WO2014140105A1 (en) 2013-03-13 2014-09-18 D2 Bioscience Group Ltd. Materials and compositions for dental cements and filler materials
WO2014161002A2 (en) 2013-03-29 2014-10-02 Onefocus Technology, Llc Drug delivery from contact lenses with a fluidic module
CA2911298C (en) 2013-05-06 2019-09-17 Kaohsiung Chang Gung Memorial Hospital A pharmaceutical composition comprising atropine and nsaid for treating myopia
SMT201900223T1 (it) 2013-05-17 2019-07-11 Incyte Corp Sale di bipirazolo come inibitore di jak
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
DE102013218802B4 (de) 2013-09-19 2018-06-28 Aero Pump Gmbh Abgabevorrichtung für Fluide aus einem Fluidbehälter
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20160009705A1 (en) 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
JP6660939B2 (ja) 2014-08-13 2020-03-11 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 点眼剤からの保存剤除去
DE102015104646B3 (de) 2015-03-26 2016-06-30 Aero Pump Gmbh Abgabevorrichtung für ein Fluid
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
ES2929368T3 (es) 2016-05-25 2022-11-28 Singapore Health Serv Pte Ltd Composición acuosa que contiene atropina
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
MX387723B (es) 2016-09-19 2025-03-18 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
JP2020509085A (ja) 2017-02-21 2020-03-26 シンガポール ヘルス サービシーズ プライベート リミテッド アトロピンを含む、近視の発症を予防するまたは遅らせるための組成物および方法
RU2745603C1 (ru) 2017-05-11 2021-03-29 Невакар Инк. Фармацевтические композиции атропина
WO2019018749A1 (en) 2017-07-20 2019-01-24 Alan Laboratories, Inc. COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA
AU2018371787A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
JP2023505841A (ja) 2019-12-16 2023-02-13 シドネキシス，インク． Ｄ２ｏを含む眼科用組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220288114A1 (en) * 2019-07-11 2022-09-15 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods

Also Published As

Publication number Publication date
US11896588B2 (en) 2024-02-13
WO2015200361A1 (en) 2015-12-30
US20210059998A1 (en) 2021-03-04
SMT202200447T1 (it) 2023-01-13
KR102506109B1 (ko) 2023-03-03
US10842787B2 (en) 2020-11-24
KR20240144477A (ko) 2024-10-02
PT3160471T (pt) 2022-08-09
EP3160471A1 (en) 2017-05-03
JP2025131595A (ja) 2025-09-09
ES2924243T3 (es) 2022-10-05
JP6678362B2 (ja) 2020-04-08
JP7505888B2 (ja) 2024-06-25
KR102710491B1 (ko) 2024-09-25
US20190091213A1 (en) 2019-03-28
NO2025049I1 (no) 2025-11-26
US20180042911A1 (en) 2018-02-15
US9770447B2 (en) 2017-09-26
TWI867694B (zh) 2024-12-21
SI3160471T1 (sl) 2022-10-28
KR20210116688A (ko) 2021-09-27
HRP20220972T1 (hr) 2022-11-25
BR112016030368B1 (pt) 2022-11-01
US20180193326A1 (en) 2018-07-12
TW202510877A (zh) 2025-03-16
CN110638749A (zh) 2020-01-03
SG10201707617VA (en) 2017-10-30
EP3160471A4 (en) 2018-04-04
US20230092957A1 (en) 2023-03-23
TW201613588A (en) 2016-04-16
HUS2500044I1 (hu) 2025-12-28
DK3160471T3 (da) 2022-08-15
FR25C1045I1 (fr) 2026-01-02
US20230091109A1 (en) 2023-03-23
BR112016030368A2 (pt) 2018-07-17
US10201534B2 (en) 2019-02-12
JP2026064997A (ja) 2026-04-14
HUE059521T2 (hu) 2022-11-28
US20210213008A9 (en) 2021-07-15
US20230093205A1 (en) 2023-03-23
US20240165098A1 (en) 2024-05-23
US10076515B2 (en) 2018-09-18
JP2020097599A (ja) 2020-06-25
US10864208B2 (en) 2020-12-15
KR20200001612A (ko) 2020-01-06
TWI763620B (zh) 2022-05-11
EP3689350A1 (en) 2020-08-05
JP2024050526A (ja) 2024-04-10
IL249643B (en) 2021-10-31
US20160339007A1 (en) 2016-11-24
CN106572998B (zh) 2019-11-08
TW202237110A (zh) 2022-10-01
US20150366854A1 (en) 2015-12-24
EP3160471B1 (en) 2022-06-01
US11382909B2 (en) 2022-07-12
US9421199B2 (en) 2016-08-23
US11596625B2 (en) 2023-03-07
US20190298707A1 (en) 2019-10-03
SG11201610682UA (en) 2017-01-27
TW202412797A (zh) 2024-04-01
PL3160471T3 (pl) 2022-09-26
US20200085813A1 (en) 2020-03-19
CN115192520A (zh) 2022-10-18
JP2022062045A (ja) 2022-04-19
CY1125505T1 (el) 2026-02-25
US11883390B2 (en) 2024-01-30
TWI855319B (zh) 2024-09-11
CA2953363A1 (en) 2015-12-30
CN106572998A (zh) 2017-04-19
US11890277B2 (en) 2024-02-06
RS63486B1 (sr) 2022-09-30
EP4115884A1 (en) 2023-01-11
JP2017522292A (ja) 2017-08-10
SG10201913976SA (en) 2020-03-30
IL249643A0 (en) 2017-02-28
KR20170018962A (ko) 2017-02-20
LT3160471T (lt) 2022-11-10
FIC20250034I1 (fi) 2025-11-28

Similar Documents

Publication Publication Date Title
US11883390B2 (en) Ophthalmic composition
US20240398705A1 (en) Ophthalmic composition
US20160009705A1 (en) Ophthalmic composition
HK40029411A (en) Ophthalmic composition comprising atropine or atropine sulphate
HK40083012A (en) Ophthalmic composition
HK40020212A (en) Ophthalmic composition
HK1231756A1 (en) Ophthalmic composition
HK1231756B (zh) 眼用组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200622

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613